Since Entering the Market, Prices of Costliest Medicare Part D Drugs Have Tripled

List prices for the 25 branded drugs associated with the highest Medicare Part D spending in 2021 have increased by an average of 226% since they first entered the market, according to a recent report from AARP’s Public Policy Institute. These drugs were responsible for $80.9 billion in total Medicare Part D spending in 2021.

Overall, lifetime price increases among the 25 drugs ranged from 20% to 739%, with all but one of them greatly exceeding the annual rate of inflation over the same period. The list price of Enbrel (etanercept), a treatment for rheumatoid arthritis and psoriatic arthritis, skyrocketed by 701% since entering the market in 1998.

© 2024 MMIT
Jinghong Chen

Jinghong Chen Reporter

Jinghong produces infographics and data stories on health insurance and specialty pharmacy for AIS Health. She graduated from Missouri School of Journalism with a focus on data journalism and international reporting. Before joining AIS in 2018, she worked at WBEZ, Al Jazeera English and The New York Times Chinese.

Related Posts

medicare-part-d
September 7

Medicare Part D Sponsors Grapple With Unknowns as Drug Price Negotiations Begin

READ MORE
doctor-woman-hands-holding-pills-and-piggy-bank-over-blue-parmacy-background
July 6

CMS Unveils New List of Drugs Subject to Medicare Part B Inflation-Based Rebates

Read More
bills-in-a-pill-bottle
March 9

Study Estimates Which Drugs Will Be in Medicare’s Price-Negotiation Crosshairs From 2026-2028

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today